Share This Page
Drug Price Trends for AUVELITY ER
✉ Email this page to a colleague
Average Pharmacy Cost for AUVELITY ER
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| AUVELITY ER 45-105 MG TABLET | 81968-0045-30 | 19.89108 | EACH | 2026-07-22 |
| AUVELITY ER 45-105 MG TABLET | 81968-0045-60 | 19.89108 | EACH | 2026-07-22 |
| AUVELITY ER 45-105 MG TABLET | 81968-0045-30 | 19.89540 | EACH | 2026-06-17 |
| AUVELITY ER 45-105 MG TABLET | 81968-0045-60 | 19.89540 | EACH | 2026-06-17 |
| AUVELITY ER 45-105 MG TABLET | 81968-0045-30 | 19.89569 | EACH | 2026-05-20 |
| AUVELITY ER 45-105 MG TABLET | 81968-0045-60 | 19.89569 | EACH | 2026-05-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
What is AUVELITY ER and its market positioning?
AUVELITY ER (dextromethorphan-bupropion extended-release) is an FDA-approved medication for major depressive disorder (MDD). Launched in 2022, it combines NMDA receptor antagonism with norepinephrine-dopamine reuptake inhibition. Its unique mechanism positions it as a differentiated option alongside established antidepressants, including SSRIs and SNRIs.
How large is the AUVELITY ER market and what are the growth drivers?
The global antidepressant market was valued at approximately $17 billion in 2021, with a compound annual growth rate (CAGR) of 2.8% projected through 2028 (QYResearch). Major drivers include increasing prevalence of depression, expanding approval for treatment-resistant depression (TRD), and growing awareness of mental health.
Within this, AUVELITY ER targets the TRD segment, estimated to account for 20-30% of depressed patients. The market potential hinges on its positioning as an alternative to existing therapies, especially given its rapid onset of action observed in trials.
What is the current sales volume and revenue for AUVELITY ER?
Initial sales data indicate early adoption, with revenues reaching approximately $15 million in the first full quarter post-launch. Prescriptions have increased at a rate consistent with initial commercial projections, driven by healthcare provider awareness campaigns and formulary placements.
Projected sales are subject to penetration rates in outpatient settings, insurance coverage, and prescriber acceptance. Analysts estimate a 2023 revenue range between $75 million and $150 million, with potential to surpass $500 million by 2025 if market penetration progresses as planned.
What are the key factors influencing price and reimbursement?
AUVELITY ER's pricing strategy is aligned with other novel antidepressants. The list price is approximately $900 for a 30-day supply, roughly 10-15% higher than comparable medications like esketamine or brexanolone. Payers generally negotiate discounts; commercial insurance and Medicare Part D coverage are crucial.
Reimbursement hinges on demonstrating comparative efficacy, safety, and cost-effectiveness. The drug has received favorable coverage in early adopter health plans, which may influence broader acceptance.
What pricing strategies are competitors using?
Competitors include esketamine (Spravato) and brexanolone (Zulresso), which command prices near $700-$900 per dose. Both drugs have faced challenges related to administration logistics and safety profiles, impacting their market share.
Generic versions of older antidepressants dominate pricing, but the premium position of AUVELITY ER is justified by its novel mechanism, rapid onset, and data on treatment-resistant populations. Pricing tiers are likely to involve value-based negotiations to optimize reimbursement.
How will market dynamics evolve through 2025?
Anticipated expansion depends on:
- Clinical guideline endorsements for AUVELITY ER in treatment algorithms.
- Success in obtaining formulary inclusion across major health plans.
- Data from ongoing real-world effectiveness studies.
- Competitive entry or biosimilars that could influence pricing pressure.
Regulatory momentum for depression drugs targeting TRD supports market growth, with some estimates suggesting the U.S. antidepressant market could grow at 4-5% CAGR over the next three years.
What are the risks affecting market growth and pricing?
Key risks include:
- Delays in broader insurance reimbursement approvals.
- Competitive erosion from established antidepressants gaining new indications.
- Safety concerns or adverse events impacting prescriber confidence.
- Pricing pressure due to generic competition for components like dextromethorphan or bupropion.
These factors can constrain revenue potential and limit pricing premiums.
Key Takeaways
- AUVELITY ER occupies a niche in treatment-resistant depression, with potential to generate significant revenue if market penetration exceeds initial estimates.
- Its pricing aligns with other innovative depression therapies, but value-based negotiations will influence final reimbursement.
- Growth depends on clinical endorsement, formulary coverage, and competing therapies' pricing strategies.
FAQs
1. What distinguishes AUVELITY ER from other antidepressants?
It combines NMDA receptor antagonism with norepinephrine-dopamine reuptake inhibition, enabling rapid onset and targeting treatment-resistant depression.
2. How does the pricing compare to competitors?
The list price is approximately $900 for a 30-day supply, slightly higher than esketamine but justified by its unique mechanism and clinical profile.
3. What are the primary barriers to market expansion?
Insurance reimbursement delays, safety concerns, and competition from both branded and generic antidepressants.
4. What is the expected growth trajectory?
Initial revenues are around $75-$150 million in 2023, with potential to reach over half a billion dollars by 2025 if market adoption accelerates.
5. How can market penetration improve?
Through clinician education, strong formulary placement, and demonstration of real-world effectiveness.
Citations:
[1] QYResearch. "Global Antidepressant Market Report, 2022".
[2] IQVIA. "Prescription Trends in Mental Health, 2022".
[3] FDA. "AUVELITY (Dextromethorphan-Bupropion) Approval Summary, 2022".
More… ↓
